
What We’re Reading: Drug Price Negotiation Participants; Low-Cost Biosimilar for Humira; Schools Stocking Naloxone
Major companies committed to joining Medicare drug price negotiations; Boehringer Ingelheim introduced a low-cost version of its adalimumab biosimilar; schools begin to stock naloxone amid rising opioid deaths among young people.
Major Drug Companies Agree to Participate in Medicare Drug Price Negotiations
Pharmaceutical companies including Johnson & Johnson, Merck, and Bristol Myers Squibb have agreed to participate in Medicare drug price negotiations with the federal government, according to the Biden administration,
Boehringer Ingelheim Launches Low-Cost Biosimilar of AbbVie's Humira in the US
Boehringer Ingelheim has released an unbranded version of its biosimilar for AbbVie's Humira (adalimumab) in the United States with a list price at an 81% discount to the reference drug,
Colorado Schools Grapple With Whether to Stock Naloxone
In Colorado, some school districts are facing a decision about whether to stock naloxone, a medication that rapidly reverses opioid overdoses, in their schools, according to
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.